Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMortgage Advice Bureau Regulatory News (MAB1)

Share Price Information for Mortgage Advice Bureau (MAB1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 864.00
Bid: 834.00
Ask: 856.00
Change: 36.00 (4.35%)
Spread: 22.00 (2.638%)
Open: 840.00
High: 876.00
Low: 822.00
Prev. Close: 828.00
MAB1 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

26 Jul 2023 07:00

RNS Number : 1758H
Mortgage Advice Bureau (Hldgs) PLC
26 July 2023
 

26 July 2023

Mortgage Advice Bureau (Holdings) plc 

("MAB" or the "Group")

Trading Update 

Mortgage Advice Bureau (Holdings) plc (AIM: MAB1) today issues a trading update for the six months ended 30 June 2023, ahead of publishing its interim results on 26 September 2023.

Group revenue for the six months ended 30 June 2023 was up 21% to £116m (H1 2022: £96.5m), with organic growth of 1% despite the market seeing a 40% drop in new mortgage approvals following the mini-budget in September 2022.

The total adviser number as at 30 June 2023 was down 6%, as expected, to 2,1091 (31 December 2022: 2,254). The average number of mainstream2 advisers during the period increased by 4% to 1,966 (H1 2022: 1,890), and on an organic basis the average number of mainstream advisers reduced by 4% to 1,814 (H1 2022: 1,890), with a circa 5% increase in organic revenue per adviser.

Due to the market turmoil that followed the mini-budget, we entered 2023 with a lower than expected pipeline of written mortgages and new Appointed Representative ("AR") firms. In addition, our existing AR firms focused on efficiency and paused recruitment, leading to a reduction in adviser numbers. 

UK gross new mortgage lending for the first five months of the year was 28% lower than in the same period in 2022, as rising costs of living and higher interest rates created further affordability constraints and reduced consumer confidence. The residential purchase segment was down 30%, residential re-mortgaging down 18% and buy-to-let down 46%. Re-financing (re-mortgaging and product transfers combined) activity performed better overall as it was bolstered by product transfers, with product transfer lending data, currently only available for the first quarter of the year, showing an increase of 12% for Q1 2023 compared to Q1 2022.

UK Gross new mortgage lending for the five months to 31 May, £bn

2023

2022

% (+/-)

Residential purchase

44.0

62.8

-30

Residential re-mortgage

28.8

35.2

-18

Buy-to-let

12.1

22.6

-46

Other

4.6

4.3

+7

Total

89.5

124.8

-28

Source: UK Finance

The strength of the MAB model has again ensured a significant outperformance of the market and a continued growth in the share of gross new mortgage lending to 8% for the five months ended 31 May 20233 (H1 2022: 6.8%), despite the expected reduction in overall adviser numbers. The Group continues to grow its market share due to the high quality of its AR firms and its strong and resilient lead sources.

Current trading and outlook

The new mortgage approvals reported in Q2 2023 suggested that activity levels had started to improve. However, market conditions are now likely to toughen further in H2 2023, driven by a continued rise in interest rates and fewer consumers opting to purchase or move home at a time when mortgage rates are at or close to peak levels in this current interest rate cycle. However, we expect re-financing will continue to perform strongly.

The underlying level of demand for home ownership and home moves remains strong, and we are confident that once inflation is under control and mortgage rates have peaked or start to fall back, we will see demand and activity strengthen again. It is too early to anticipate when that will happen, but when it does MAB will have increased market share and will be in a very strong position to capitalise on the recovery and the inevitable catch up in house purchase transactions that will follow.

H1 has seen our new AR pipelines build back to pre-mini-budget levels and we expect this strong activity to continue throughout H2. Organic adviser growth will return when the economic outlook is more certain, which will enable our AR firms to plan with far more confidence.

Despite the strengthening H2 headwinds, trading is currently in line with market expectations and the Group is well positioned to deliver further growth as the market recovers.

Peter Brodnicki, CEO of MAB, commented:

"We had hoped to be in a period of interest rate stability as we entered Q3, followed by a resumption in organic adviser growth in Q4. Instead, we find ourselves in an environment of continuing interest rate rises, reduced affordability, and cost of living increases, all of which are naturally impacting consumer confidence. Despite strong underlying demand for property, some buying decisions are understandably being delayed by our customers until we have a more stable economic and interest rate environment.

"Despite the additional market pressure, I am delighted with how MAB is performing and how our market share continues to grow. Re-mortgages and increasing numbers of product transfers currently represent around 60% of our written transaction volumes. This will deliver MAB a greater number of re-financing opportunities in the medium term, with the Group's advisers performing particularly strongly in this area.

"Despite the signs of a market recovery being further off than we expected three months ago, business efficiency continues to increase, adviser productivity has been maintained, and all strategic initiatives continue to progress well. The Group is well positioned to deliver further growth as the market recovers."

Enquiries:

Mortgage Advice Bureau (Holdings) plc +44 (0)1332 525007

Peter Brodnicki, Chief Executive Officer

Ben Thompson, Deputy Chief Executive Officer

Lucy Tilley, Chief Financial Officer

Nominated Adviser and Joint Broker: +44 (0)20 7260 1000

Numis Securities Limited

Stephen Westgate / Giles Rolls

Joint Broker:

Peel Hunt LLP

Andrew Buchanan / Mike Burke +44 (0) 20 7418 8900

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). 

1 Includes a total of 188 advisers as at 30 June 2023 who are either directly authorised or later life advisers. For both directly authorised and later life advisers the fees received by MAB represent the net income received by MAB as there are no commission payouts made by MAB.

2 Excludes directly authorised advisers and later life advisers.

3 UK gross new mortgage lending values for June 2023 are not yet available.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSADAIEFIV
Date   Source Headline
17th Oct 20187:00 amRNSReplacement: Director/PDMR Shareholding
16th Oct 20187:00 amRNSDirector/PDMR Shareholding
4th Oct 20182:24 pmRNSHolding(s) in Company
4th Oct 20188:11 amRNSHolding(s) in Company
28th Sep 20182:16 pmRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSHalf-year Report
14th Sep 20184:43 pmRNSDirector/PDMR Shareholding
14th Sep 20187:00 amRNSChange of Adviser
31st Aug 201811:08 amRNSDirector/PDMR Shareholding
28th Aug 20184:10 pmRNSHolding(s) in Company
14th Aug 20183:13 pmRNSDirector/PDMR Shareholding
2nd Aug 201812:07 pmRNSSecond Price Monitoring Extn
2nd Aug 201812:02 pmRNSPrice Monitoring Extension
31st Jul 20185:05 pmRNSDirector/PDMR Shareholding
26th Jul 20187:00 amRNSPre-close Trading Update
16th Jul 20182:34 pmRNSDirector/PDMR Shareholding
2nd Jul 20186:43 pmRNSHolding(s) in Company
2nd Jul 20186:43 pmRNSHolding(s) in Company
29th Jun 20185:06 pmRNSDirector/PDMR Shareholding
14th Jun 20185:28 pmRNSDirector/PDMR Shareholding
7th Jun 20187:00 amRNSBoard Appointment
31st May 20186:16 pmRNSDirector/PDMR Shareholding
23rd May 20184:08 pmRNSDirector/PDMR Shareholding
17th May 20183:10 pmRNSResult of AGM
17th May 201810:31 amRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSAGM Statement
15th May 20187:00 amRNSDirector/PDMR Shareholding
30th Apr 20184:34 pmRNSDirector/PDMR Shareholding
17th Apr 20182:08 pmRNSPosting of Report and Accounts & Notice of AGM
16th Apr 20183:49 pmRNSDirector/PDMR Shareholding
10th Apr 20186:20 pmRNSGrant of options and Director dealing
6th Apr 20187:00 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSBoard Appointment
29th Mar 20183:23 pmRNSDirector/PDMR Shareholding
28th Mar 20187:26 amRNSBlock Admission Application
20th Mar 20187:00 amRNSFinal Results for the year ended 31 December 2017
15th Mar 20189:38 amRNSDirector/PDMR Shareholding
28th Feb 20184:00 pmRNSDirector/PDMR Shareholding
15th Feb 20188:07 amRNSDirector/PDMR Shareholding
31st Jan 20186:15 pmRNSDirector/PDMR Shareholding
22nd Jan 20187:00 amRNSPre-close Trading Update
15th Jan 20183:31 pmRNSDirector/PDMR Shareholding
8th Jan 20188:56 amRNSNon-Executive Director Board changes
28th Dec 20177:00 amRNSDirector/PDMR Shareholding
14th Dec 20175:59 pmRNSDirector/PDMR Shareholding
30th Nov 20174:23 pmRNSDirector/PDMR Shareholding
14th Nov 20174:31 pmRNSDirector/PDMR Shareholding
13th Nov 201711:21 amRNSHolding(s) in Company
31st Oct 20176:24 pmRNSDirector/PDMR Shareholding
16th Oct 20174:29 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.